Trials / Withdrawn
WithdrawnNCT00690911
Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis
A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wake Forest University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to see if Humira is effective and safe in the treatment of sarcoidosis.
Detailed description
The primary objective of this study is to evaluate the safety and efficacy of adalimumab for the treatment of cutaneous sarcoidosis. A secondary objective is to study gene expression in sarcoidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | adalimumab | 40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations. |
Timeline
- First posted
- 2008-06-05
- Last updated
- 2017-11-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00690911. Inclusion in this directory is not an endorsement.